Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN® nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.
October 2, 2017
1 Min Read
.png?width=850&auto=webp&quality=95&format=jpg&disable=upscale "ChromaDex Announces Top Line Results of its Second Human Clinical Trial")
ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN® nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.
You May Also Like
Recommended
Sponsored Content
May 1, 2024
.png?width=800&auto=webp&quality=80&disable=upscale)